Built on our proprietary ImmTAX platform, we have a diverse pipeline of bispecific therapies across a broad range of indications.
Our pipeline includes clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects
Tebentafusp
/ Target: gp100 (A02)Adjuvant uveal (ocular)
melanoma
ATOM sponsored by EORTC
IND-enabling
Phase 1
Phase 2
Phase 3
2L+ advanced cutaneous melanoma
TEBE-AM
IND-enabling
Phase 1
Phase 2
Phase 3
Brenetafusp (IMC-F106C)
/ Target: PRAME (A02)1L advanced cutaneous melanoma
PRISM-MEL-301
IND-enabling
Phase 1
Phase 2
Phase 3
Ovarian
IND-enabling
Phase 1
Phase 2
Phase 3
NSCLC2
IND-enabling
Phase 1
Phase 2
Phase 3
Additional solid tumors
IND-enabling
Phase 1
Phase 2
Phase 3
IMC-P115C
/ Target: PRAME-HLE (A02)Multiple solid tumors
IND-enabling
Phase 1
Phase 2
Phase 3
IMC-R117C
/ Target: PIWIL1 (A02)Colorectal and GI cancers
IND-enabling
Phase 1
Phase 2
Phase 3
IMC-M113V
/ Target: Gag (A02)Human Immunodeficiency Virus (HIV)
IND-enabling
Phase 1
Phase 2
Phase 3
IMC-I109V
/ Target: Envelope (A02)Hepatitis B Virus (HBV)
IND-enabling
Phase 1
Phase 2
Phase 3
IMC-S118AI
/ Target: PPI (A02)Type 1 Diabetes
IND-enabling
Phase 1
Phase 2
Phase 3
IMC-U120AI
/ Target: CD1a (non-HLA restricted)Atopic Dermatitis
IND-enabling
Phase 1
Phase 2
Phase 3
Date last updated: January 2026
2 NSCLC = Non-small cell lung cancer.
Disclaimer
All trademarks, company and product names or logos are the property of their respective owners. The efficacy and safety of the molecules under investigation have not yet been established. There is no guarantee that pipeline molecules will receive approval and become commercially available for the uses being investigated as drug development is uncertain and agents in development may be terminated along the development process. The above information is accurate as of September 2024.